$OPK News

OPKO Health Subsidiary EirGen Pharma Expands Agreement With Nicoya Therapeutics To Commercialize RAYALDEE In China

Barrington Research Downgrades OPKO Health to Market Perform

OPKO Health Q1 2026 Earnings Call: Complete Transcript

OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript

OPKO Health Inc (NASDAQ:OPK) Misses Q1 Revenue Estimates, Shares Slide After Hours

OPKO Health Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $551.214M Est

OPKO Health Sees Q2 Sales $127.000M-$132.000M vs $136.329M Est

OPKO Health Q1 EPS $(0.07), Inline, Sales $124.200M Miss $130.514M Estimate

Opko Health Subsidiary ModeX Therapeutics Begins MDX2003 Clinical Trial With First Dosing For Relapsed Or Refractory B-Cell Lymphoma

OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment

OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19

OPKO Health's ModeX Therapeutics Says First Participants Dosed In Phase 1 Clinical Trial Evaluating MDX2301 For Prevention Of COVID-19

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

How The OPKO Health (OPK) Story Is Shifting With Mixed Analyst Signals

OPKO Health: The Waiting Game Continues

Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy

Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates